Clinical Trial Update: MAP-guided Preemptive Therapy of aGvHD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating MAP-guided preemptive therapy for acute graft-versus-host disease (GVHD) following stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Stem Cell Transplantation Complications

Snippet

Sponsor: Sichuan University | Conditions: GVHD,Acute, Stem Cell Transplant Complications | Phase 2 | Status: UNKNOWN